AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19735523 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime SPF 30 lotion
Number of subjects: 77
Study 19735523 — intervention group
Group type: EXPERIMENTAL
Intervention: Night cream
Number of subjects: 77
Study 19735523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye cream
Number of subjects: 77
Study 19735523 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrinkle treatment
Number of subjects: 77
Study 18035071 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 1000
Study 18035071 — intervention group
Group type: COMPARATOR
Intervention: Control (HM off)
Number of subjects: 1000
Study 15139891 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight Programme intervention
Number of subjects: 1256
Study 15139891 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterweight Programme intervention (fully compliant patients)
Number of subjects: 1256
Study 15139891 — intervention group
Group type: COMPARATOR
Intervention: Control group (deferred intervention)
Number of subjects: 1256
Study 11308999 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ng. ml‐1 plasma remifentanil
Number of subjects: 20
Study 11308999 — intervention group
Group type: COMPARATOR
Intervention: 4 ng. ml‐1 plasma remifentanil (Control)
Number of subjects: 20
Study 9920455 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐nitro‐L‐arginine methyl ester (L‐NAME) 40 mg/kg injected plus 50 mg/kg infused over 60 min
Number of subjects: 21
Study 9920455 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 21
Study 8049459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 60
Study 8049459 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 60
Study 8049459 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial therapy
Number of subjects: 60
Study 3393023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive maintenance therapy (chemotherapy: cytosine arabinoside plus 6-thioguanine, 100 mg/m2 every 12 hr for a variable number of days, repeated every three months for three or more years)
Number of subjects: 86
Study 3393023 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 86
Study 3393023 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy plus chemotherapy (control group)
Number of subjects: 86
Study 3393023 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy plus chemotherapy (control group)
Number of subjects: 86
Study 31829279 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step reminder system for serum lithium monitoring
Number of subjects: 0
Study 31829279 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29853416 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Infusion (SI) - 0.2 mg kg−1 minute−1 for 240 minutes after a bolus of 2 mg kg–1
Number of subjects: 6
Study 29853416 — intervention group
Group type: COMPARATOR
Intervention: 3-step Infusion - 0.4 mg kg−1 minute−1 for 10 minutes, then 0.3 mg kg−1 minute−1 for 30 minutes, and then 0.2 mg kg−1 minute−1 for 200 minutes after a bolus of 2 mg kg–1
Number of subjects: 6
Study 27565240 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Number of subjects: 60
Study 27565240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25537784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (one session a day for 3 days)
Number of subjects: 36
Study 25537784 — intervention group
Group type: COMPARATOR
Intervention: Massage on the local neck region (5 min each session, three times a day for 3 days)
Number of subjects: 36
Study 22004585 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral EDTA-Na-Fe (60 mg Fe/dose, three times a week) and a 2-week course of colloidal bismuth subcitrate, amoxicillin and metronidazole
Number of subjects: 80
Study 22004585 — intervention group
Group type: COMPARATOR
Intervention: EDTA-Na-Fe alone
Number of subjects: 80
Study 18823410 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin intervention
Number of subjects: 343
Study 18823410 — intervention group
Group type: COMPARATOR
Intervention: Placebo vs. active drug assignment
Number of subjects: 343
Study 18823410 — intervention group
Group type: EXPERIMENTAL
Intervention: Study procedures
Number of subjects: 343
Study 18823410 — intervention group
Group type: COMPARATOR
Intervention: Random assignment
Number of subjects: 343
Study 18823410 — intervention group
Group type: EXPERIMENTAL
Intervention: Close observation for diabetes onset
Number of subjects: 343
Study 18823410 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 343
Study 17643765 — intervention group
Group type: EXPERIMENTAL
Intervention: New orthodontic appliance with velar extension
Number of subjects: 11
Study 17643765 — intervention group
Group type: COMPARATOR
Intervention: Conventional appliance without velar extension
Number of subjects: 11
Study 15067622 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 95
Study 15067622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 95
Study 15067622 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 95
Study 15067622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 12079930 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine dose of thyroxin administered orally or via nasogastric tube in the perioperative period, no supplemental dose used.
Number of subjects: 25
Study 9617439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injection of vasoactive intestinal polypeptide (VIP) at concentrations of 1.5 x 10(‐7), 1.5 x 10(‐6), and 1.5 x 10(‐5) M; combined with acetylcholine (ACh) at 5.5 x 10(‐6) M.
Number of subjects: 3
Study 9617439 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous injection of VIP and ACh
Number of subjects: 3
Study 9617439 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (0.9% sodium chloride and ACh)
Number of subjects: 3
Study 9617439 — intervention group
Group type: COMPARATOR
Intervention: ACh administration
Number of subjects: 3
Study 9161245 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage, nonsubmerged ITI implants
Number of subjects: 38
Study 2721119 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre
Number of subjects: 2
Study 2721119 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained handgrip test
Number of subjects: 2
Study 2721119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 2
Study 2721119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress test
Number of subjects: 2
Study 2721119 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (efferent parasympathetic blockade)
Number of subjects: 2
Study 31924255 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised Attention Bias Modification Training (ABMT)
Number of subjects: 45
Study 31924255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 45
Study 31924255 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 45
Study 30898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGFBP-1 levels (highest quartile)
Number of subjects: 620
Study 30898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IGFBP-1 levels (after adjustment for BMI)
Number of subjects: 620
Study 30898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of carbohydrates, plant protein, and milk protein
Number of subjects: 620
Study 30898176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intakes of meat protein and fat
Number of subjects: 620
Study 30898176 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 levels
Number of subjects: 620
Study 29017585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol and ibuprofen
Number of subjects: 0
Study 26012878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis in specialized ambulances
Number of subjects: 0
Study 23863677 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-scalp grafting
Number of subjects: 13
Study 23863677 — intervention group
Group type: COMPARATOR
Intervention: Control (vaseline gauze)
Number of subjects: 13
Study 20938210 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 69
Study 20938210 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 69
Study 20938210 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy persons)
Number of subjects: 69
Study 19702644 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 23
Study 19702644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17530974 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified drop jumps added to warm-up
Number of subjects: 13
Study 15524423 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 56
Study 15524423 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 11181673 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m(2) + cisplatin 75mg/m(2) + granulocyte colony-stimulating factor (Arm A)
Number of subjects: 210
Study 11181673 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 135 mg/m(2) + cisplatin 75 mg/m(2) (Arm B)
Number of subjects: 210
Study 9037637 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (3 micrograms/kg per min)
Number of subjects: 11
Study 8290910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 86
Study 8290910 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 86
Study 3827416 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg administered sublingually
Number of subjects: 25
Study 3827416 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg administered sublingually after 120 minutes to placebo-pretreated patients
Number of subjects: 25
Study 3827416 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive medications and bed rest (Control)
Number of subjects: 25
Study 3827416 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (study patients)
Number of subjects: 25
Study 31885346 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS stimulation (30 sessions, 20 minutes each at 2-mA)
Number of subjects: 1
Study 31885346 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (30 sessions, 20 minutes each)
Number of subjects: 1
Study 30014589 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp + IAsp
Number of subjects: 362
Study 30014589 — intervention group
Group type: COMPARATOR
Intervention: IDet + IAsp
Number of subjects: 362
Study 27584877 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials adapted into multimedia formats and capacity building for Head Start agencies
Number of subjects: 540
Study 27584877 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and guidance for sleep problems (secondary prevention feasibility study)
Number of subjects: 540
Study 24889103 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-speech oro-motor exercises (NSOMExs) included in the intervention for Group B, delivered in eight home-based SLT sessions.
Number of subjects: 39
Study 24889103 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention without NSOMExs for Group A, delivered in eight home-based SLT sessions.
Number of subjects: 39
Study 23159232 — intervention group
Group type: COMPARATOR
Intervention: No darbepoetin alfa doses
Number of subjects: 2019
Study 23159232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of darbepoetin alfa
Number of subjects: 2019
Study 23159232 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4 doses of darbepoetin alfa
Number of subjects: 2019
Study 23159232 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or more doses of darbepoetin alfa
Number of subjects: 2019
Study 18793814 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 49346
Study 17904834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with salmeterol and fluticasone
Number of subjects: 1606
Study 16614542 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 25, 50, and 100 mg daily
Number of subjects: 10
Study 16614542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12657970 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid infusion for 48 hours after significant head injury
Number of subjects: 3000
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorders
Number of subjects: 4075
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 4075
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatoform disorders
Number of subjects: 4075
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective disorders
Number of subjects: 4075
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorders
Number of subjects: 4075
Study 10989807 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional disorders
Number of subjects: 4075
Study 9378830 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified sodium chlorite (ASC) mouthrinses
Number of subjects: 35
Study 9378830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.12%
Number of subjects: 35
Study 9378830 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (water)
Number of subjects: 35
Study 8436235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile vaseline ointment
Number of subjects: 179
Study 8436235 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 179
Study 3017391 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 25
Study 3017391 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 25
Study 30293467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine-based local anesthesia (preoperative intramuscular injection of dezocine)
Number of subjects: 120
Study 30293467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dezocine injection)
Number of subjects: 120
Study 26694963 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study 26694963 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical practice (CMP)
Number of subjects: 0
Study 24884578 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 60
Study 24884578 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin or anti-staphylococcal penicillin)
Number of subjects: 60
Study 24884578 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 60
Study 22579798 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset net
Number of subjects: 2115
Study 22579798 — intervention group
Group type: COMPARATOR
Intervention: Untreated net
Number of subjects: 2115
Study 20298851 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine treatment
Number of subjects: 60
Study 20298851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18367764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hemocoagulase
Number of subjects: 72
Study 16313250 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 15
Study 16313250 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 15
Study 11203783 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V
Number of subjects: 46
Study 11203783 — intervention group
Group type: COMPARATOR
Intervention: Single Bond
Number of subjects: 46
Study 9553910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 10
Study 9553910 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MP)
Number of subjects: 10
Study 9553910 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (OH-C)
Number of subjects: 10
Study 9553910 — intervention group
Group type: COMPARATOR
Intervention: Drug-free vehicle
Number of subjects: 10
Study 7851225 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient diabetes education program led by a certified diabetes educator
Number of subjects: 0
Study 7851225 — intervention group
Group type: COMPARATOR
Intervention: Control medical units with no structured diabetes education program
Number of subjects: 0
Study 3142562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening at intervals of 18‐24 months
Number of subjects: 42183
Study 3142562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 42183
Study 3142562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 42183
Study 7729207 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT) in patients with alcoholic cirrhosis (AC)
Number of subjects: 136
Study 7729207 — intervention group
Group type: COMPARATOR
Intervention: Liver transplantation (LT) in patients with non-alcoholic cirrhosis (NAC)
Number of subjects: 136
Study 7729207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who interrupted alcohol consumption for at least 3 months before LT
Number of subjects: 136
Study 7729207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alcoholic cirrhosis (AC)
Number of subjects: 136
Study 665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement using three different instrument types, each with three readings.
Number of subjects: 0
Study 665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis of blood pressure on height and log weight.
Number of subjects: 0
Study 665656 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal observation of blood pressure changes over time.
Number of subjects: 0
Study 31473412 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density of fruit/vegetable vendors within 400m
Number of subjects: 5764
Study 31473412 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density of highly processed/take-away food vendors within 400m
Number of subjects: 5764
Study 31473412 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood accessibility
Number of subjects: 5764
Study 28176235 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg SC sumatriptan (DFN-11)
Number of subjects: 20
Study 28176235 — intervention group
Group type: COMPARATOR
Intervention: 6 mg SC sumatriptan
Number of subjects: 20
Study 26244386 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) monotherapy
Number of subjects: 50
Study 23423871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) plus topical tazarotene 0.1% cream
Number of subjects: 25
Study 23423871 — intervention group
Group type: COMPARATOR
Intervention: Topical tazarotene 0.1% cream
Number of subjects: 25
Study 21248756 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention program including HTN education and dietary and lifestyle guidance
Number of subjects: 1632
Study 21248756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1632
Study 21248756 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention program including HTN education and lifestyle modifications
Number of subjects: 1632
Study 19780346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal epileptiform activity (IEA) and EEG dysrhythmias
Number of subjects: 0
Study 19780346 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological techniques including Magnetoencephalography (MEG), EEG neurofeedback, and data fusion models (EEG-fMRI-BOLD)
Number of subjects: 0
Study 17205478 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 98
Study 17205478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 15057741 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000-1200 mg/day
Number of subjects: 604
Study 15057741 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin
Number of subjects: 604
Study 15057741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin dose reduction from > or =80% to < or =60% of the starting dose during the first 20 weeks of treatment
Number of subjects: 604
Study 15057741 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon or ribavirin dose reduction after week 20
Number of subjects: 604
Study 11172509 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 3% 2-chloroprocaine
Number of subjects: 27
Study 11172509 — intervention group
Group type: COMPARATOR
Intervention: 1.5% lidocaine
Number of subjects: 27
Study 9663362 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg twice daily (increased to 75 mg if needed)
Number of subjects: 145
Study 9663362 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg once daily (increased to 40 mg if needed)
Number of subjects: 145
Study 7529528 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 6
Study 7529528 — intervention group
Group type: EXPERIMENTAL
Intervention: granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF)
Number of subjects: 6
Study 7529528 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF and rhGM-CSF
Number of subjects: 6
Study 3278431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) - prednisone (pred)
Number of subjects: 246
Study 3278431 — intervention group
Group type: COMPARATOR
Intervention: Antilymphoblast-globulin (ALG) - azathioprine (AZA) - prednisone
Number of subjects: 246
Study 3278431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic recipients of cadaver grafts
Number of subjects: 246
Study 3278431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetics
Number of subjects: 246
Study 3278431 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 246
Study 30912213 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixed analog insulin (Humalog® Mix50/50™)
Number of subjects: 40